(This story is part of the cover package in the November-December issue of MJBizMagazine.)
If marijuana is moved from Schedule 1 to Schedule 3 of the Controlled Substances Act, that would expand both access and product selection for medical marijuana patients.
But rescheduling likely wouldn’t impact how state-regulated MMJ dispensaries operate.
ADVERTISEMENT
“Schedule 3 allows essentially a new pathway for cannabis to be in the marketplace, which is through an FDA-approved drug channel,” said Amy Rubenstein, a partner with the international law firm Dentons.
Pharma pipeline
Rubenstein explained that moving marijuana to Schedule 3 would make it easier for companies to develop cannabis-based drugs and get U.S. Food and Drug Administration approval for them.
Once drugs have FDA approval, they can be purchased with a physician’s prescription at federally licensed pharmacies.
She added that developing drugs, going through the requisite studies and getting approval takes years, so it would be
Read full article on Marijuana Business Daily
